Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients.
It is a challenging task to verify and quantify potential biomarkers expressed at elevated levels in sera from cancer patients. An immunoaffinity-mass spectrometry-based approach has been developed using antibodies to enrich proteins of interest from sera followed by mass spectrometry-based quantification. Antibodies specific to the protein of interest were immobilized to hydrazide resin via the carbohydrate moiety on the Fc region of the antibody. Captured proteins were eluted, reduced, alkylated, and digested with trypsin. Peptides were analyzed by LC coupled with multiple reaction monitoring approach, and quantification was achieved by the addition of stable isotope-labeled (heavy) standard peptides. Using this methodology, we were able to achieve a linear response from 15 to 250 ng/ml for carcinoembryonic antigen (CEA), a known tumor biomarker. Moreover we observed elevated levels of CEA in sera samples from lung cancer patients that to our knowledge is the first time that circulating CEA has been detected by mass spectrometry-based analysis. This approach was further applied to potential protein biomarkers discovered from tumor cell lines and tumor tissues. A linear response was obtained from a multiplex spiking experiment in normal human sera for secretory leukocyte peptidase inhibitor (4-500 ng/ml), tissue factor pathway inhibitor (TFPI) (42-1000 ng/ml), tissue factor pathway inhibitor 2 (TFPI2) (2-250 ng/ml), and metalloproteinase inhibitor 1 (TIMP1) (430-1000 ng/ml). A replicate experiment for a single concentration value yielded a relative coefficient of variation better than 11% for TFPI, secretory leukocyte peptidase inhibitor, and TFPI2. The expression level of the proteins in lung cancer patient sera was assayed by an immunoaffinity-multiple reaction monitoring method, and the results were comparable with those obtained from ELISA. This immunoaffinity-mass spectrometry-based quantification approach thus provides a specific and accurate assay for verifying the expression of potential biomarkers in patient serum samples especially for those proteins for which the necessary reagents for ELISA development are unavailable.
Nicol
Gordon R
GR
Celera, Rockville, Maryland 20850, USA.
Han
Mark
M
Kim
Jun
J
Birse
Charles E
CE
Brand
Erin
E
Nguyen
Anh
A
Mesri
Mehdi
M
FitzHugh
William
W
Kaminker
Patrick
P
Moore
Paul A
PA
Ruben
Steven M
SM
He
Tao
T
D000595:Amino Acid Sequence; D000912:Antibodies, Neoplasm / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D002846:Chromatography, Affinity / Q000379:methods*; D006801:Humans; D008074:Lipoproteins / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology; D013058:Mass Spectrometry / Q000379:methods*; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000097:blood* / Q000737:chemistry; D009367:Neoplasm Staging; D010455:Peptides / Q000032:analysis / Q000737:chemistry; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000097:blood; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood
D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D008074:Lipoproteins; D009363:Neoplasm Proteins; D010455:Peptides; C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor; D019715:Tissue Inhibitor of Metalloproteinase-1; C051928:lipoprotein-associated coagulation inhibitor